Wockhardt Ltd 2020 AR2
The report outlines Wockhardt Limited's financial and operational performance for the fiscal year 2019-2020. Key highlights include the strategic divestment of a part of its domestic branded business to Dr. Reddy's Laboratories for ‹1,850 crore to focus on chronic segments and niche antibiotics. The company received DCGI approval for two new antibiotics, EMROK and EMROK O, developed in India. Additionally, Wockhardt's NCE WCK 6777 was granted QIDP status by the US FDA, making it the only company globally with six antibiotics holding this status. The company also continued its CSR initiatives through the Wockhardt Foundation, touching millions of lives.
Company: Wockhardt Ltd
Sector: Manufacturing
Country: India
Year: 2020
Type: AR2
Pages: 224
Back to company
Wockhardt Ltd
Annual Report
The report outlines Wockhardt Limited's financial and operational performance for the fiscal year 2019-2020. Key highlights include the strategic divestment of a part of its domestic branded business to Dr. Reddy's Laboratories for ‹1,850 crore to focus on chronic segments and niche antibiotics. The company received DCGI approval for two new antibiotics, EMROK and EMROK O, developed in India. Additionally, Wockhardt's NCE WCK 6777 was granted QIDP status by the US FDA, making it the only company globally with six antibiotics holding this status. The company also continued its CSR initiatives through the Wockhardt Foundation, touching millions of lives.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Employees